Issuu

This activity is provided by Integritas Communications. This activity is supported by an educational grant from AstraZeneca. This event is neither sponsored by nor endorsed by ACG.

CLINICAL RESOURCE CENTER

ExchangeCME.com/ EoESpotlightResources

GET FREE ACCESS TO THE LATEST CME/CE ACTIVITIES, WEBINARS, EVENTS, AND MORE AT EXCHANGECME.COM.

Subscribe to our YouTube channel @exchangecme for additional informative videos. youtube.com/c/ExchangeCME

MEDICAL COMMUNICATIONS INQUIRIES info@integritasgrp.com integritasgrp.com

FACULTY

FACULTY MAUREEN BAUER, MD Associate Professor of Pediatrics Allergy & Immunology Fellowship Program Director Section of Pediatric Allergy & Immunology Children’s Hospital Colorado University of Colorado School of Medicine Aurora, Colorado

Maureen Bauer, MD, is an Associate Professor of Pediatrics at Children’s Hospital Colorado/University of Colorado School of Medicine, where she is a member of the Gastrointestinal Eosinophilic Diseases Program and serves as Director of the Allergy and Immunology Fellowship Program. Her clinical expertise includes eosinophilic esophagitis and other eosinophilic gastrointestinal disorders, food allergy, asthma, allergic rhinitis, eczema, drug allergy, and urticaria. Dr Bauer is particularly interested in food allergy and eosinophilic esophagitis and is committed to providing patientand family-centered care across the spectrum of allergic disorders.

EVAN S. DELLON, MD, MPH FACULTY

Professor of Medicine Adjunct Professor of Epidemiology University of North Carolina School of Medicine Chapel Hill, North Carolina

Evan S. Dellon, MD, MPH, is a Professor of Medicine and Adjunct Professor of Epidemiology at the University of North Carolina (UNC) School of Medicine in Chapel Hill. Dr Dellon completed an internship and residency in internal medicine at Massachusetts General Hospital and a clinical and a research fellowship in adult gastroenterology at UNC, during which he also earned a Master of Public Health degree in epidemiology from the UNC School of Public Health. He is currently Director of the UNC Center for Esophageal Diseases and Swallowing. Dr Dellon’s main research interest is in the epidemiology, pathogenesis, diagnosis, treatment, and outcomes of eosinophilic esophagitis (EoE) and eosinophilic gastrointestinal diseases (EGIDs). The goal of his research is to improve the lives of patients with EoE and EGIDs by learning how to better diagnose, treat, and monitor these conditions.

GIRISH HIREMATH, MD, MPH FACULTY

Associate Professor of Pediatrics Director, Eosinophilic Gastrointestinal Diseases Program Division of Pediatric Gastroenterology, Hepatology, and Nutrition Monroe Carell Jr. Children’s Hospital at Vanderbilt Vanderbilt University Medical Center Associate Professor of Biomedical Engineering Vanderbilt School of Engineering Vanderbilt University Nashville, Tennessee Girish Hiremath, MD, MPH, is an Associate Professor of Pediatrics and of Biomedical Engineering at Vanderbilt University and Director of the Eosinophilic Gastrointestinal Diseases Program at Monroe Carrell Jr. Children’s Hospital at Vanderbilt University Medical Center. He is a board-certified pediatric gastroenterologist and physician-scientist whose research focuses on EoE, precision medicine, and the development of novel diagnostic tools. His research integrates advanced imaging techniques, Raman spectroscopy, multiomics, and artificial intelligence to better understand disease mechanisms and develop less-invasive approaches for the diagnosis and monitoring of EoE. Dr Hiremath has received funding from the National Institutes of Health, the American College of Gastroenterology, and other national organizations and has authored numerous peer-reviewed publications. He also serves on national committees and advisory boards dedicated to advancing research and care for eosinophilic gastrointestinal diseases.

PROGRAM DESCRIPTION

PREAMBLE

EoE is a chronic immune-mediated disease with an evolving therapeutic landscape. This Science in the Spotlight™ dinner symposium begins with a dynamic whiteboard animation that engages learners and shifts clinical thinking from symptom-based management toward a mechanism-driven approach to patient assessment and treatment. Faculty will explore the role of epithelial signaling and upstream alarmin cytokines in EoE pathogenesis before examining emerging biologic therapies targeting these pathways. Through interactive polling, practical clinical application, and expert discussion, attendees will gain evidence-based strategies to improve the diagnosis, evaluation, therapeutic selection, and long-term management of patients with EoE.

TARGET AUDIENCE This educational activity has been designed to educate gastroenterology and allergy/clinical immunology clinicians who manage patients with EoE.

EDUCATIONAL OBJECTIVES Upon completion of this activity, participants will be better prepared to: • Discuss the contributions of epithelial cytokine signaling to the pathophysiology of EoE, including implications for progression risks and treatment options • Evaluate patients with suspected EoE in accordance with recent evidence-based guidelines • Describe the clinical rationale and published trial evidence for emerging biologic therapies in the treatment of EoE, including anti-TSLP agents

PHYSICIAN ACCREDITATION STATEMENT Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION Integritas Communications designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

INSTRUCTIONS TO RECEIVE CREDIT In order to receive credit for this activity, the participant must attend the live symposium/live stream and complete the posttest and program evaluation.

Integritas Communications adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated. The faculty have the following relevant financial relationships with ineligible companies: Maureen Bauer, MD Consulting Fees (eg, advisory boards): DBV, DynaMed, Sanofi/Regeneron Evan S. Dellon, MD, MPH Consulting Fees (eg, advisory boards): AbbVie, Adare/Ellodi, Alfasigma, ALK, Allakos, Amgen, AnaptysBio, Apogee, Apollo, Aqilion, Arena/ Pfizer, AstraZeneca, Bethanamist, BioCryst, Bryn, Calypso, Celgene/ Receptos/BMS, Celldex, Cyted, Domain, Eli Lilly, EsoCap, Eupraxia, Dr. Falk Pharma, Ferring, GI Reviewers, GSK, Holoclara, Invea, Knightpoint, Kymera, LucidDx, Nexstone Immunology/Uniquity, Nutricia, Parexel/ Calyx, Phathom, Regeneron, Revolo, Robarts/Alimentiv, Roivant, Sanofi, Shire/Takeda, Target RWE, Third Harmonic Bio, Upstream Bio; Contracted Research: Adare/Ellodi, Allakos, Arena/Pfizer, AstraZeneca, Celldex, Celgene/Receptos/BMS, Dr. Falk Pharma, Eupraxia, Ferring, GSK, Meritage, Miraca, Nutricia, Phathom, Regeneron, Revolo, Sanofi, Shire/Takeda, Uniquity; Other (educational grants): Allakos, Aqilion, Holoclara, Invea Girish Hiremath, MD, MPH Consulting Fees (eg, advisory boards): Amgen, AstraZeneca, Eupraxia, Kaplan Inc., Sanofi, Regeneron, Takeda

PREAMBLE

DISCLOSURES OF CONFLICTS OF INTEREST

The Integritas planners and managers have no relevant financial relationships to disclose.

DISCLOSURE OF UNLABELED USE

PREAMBLE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas Communications does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION & REFUND/ CANCELLATION POLICY There is no fee for this activity.

CONTACT INFORMATION For information about this program, please contact us at info@exchangecme.com.

SLIDES

GUIDELINES

» ACG clinical guideline: diagnosis and management of eosinophilic esophagitis. Dellon ES, et al. Am J Gastroenterol. 2025;120(1):31-59. https://pubmed.ncbi.nlm.nih.gov/39745304/

» Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference. Dellon ES, et al. Gastroenterology. 2018;155(4):1022-1033.e10. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174113/

» AGA Institute and the Joint Task Force on AllergyImmunology Practice Parameters clinical guidelines for the management of eosinophilic esophagitis. Hirano I, et al. Gastroenterology. 2020;158(6):1776-1786. https://pubmed.ncbi.nlm.nih.gov/32359562/

» Technical review on the management of eosinophilic esophagitis: a report from the AGA institute and the joint task force on allergy-immunology practice parameters. Rank MA, et al. Ann Allergy Asthma Immunol. 2020;124(5):424-440.e17. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8171057/

CLINICIAN RESOURCE

» Index of Severity for Eosinophilic Esophagitis (I-SEE) Point-of care mobile app for assessing EoE disease severity. American Gastroenterological Association.

PATIENT RESOURCES

» American Partnership for Eosinophilic Disorders (Apfed) https://apfed.org/

» Campaign Urging Research for Eosinophilic Disease (CURED) http://curedfoundation.org/

» National Organization for Rare Disorders (NORD) https://rarediseases.org/rare-diseases/eosinophilic-esophagitis/

RESOURCE CENTER

https://gastro.org/news/i-see-mobile-app/